Bausch Health Companies Inc. (BHC.TO)

CAD 10.59

(-3.73%)

Market Cap (In CAD)

3.89 Billion

Revenue (In CAD)

8.75 Billion

Net Income (In CAD)

-592 Million

Avg. Volume

465.85 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.45-15.43
PE
-
EPS
-
Beta Value
0.745
ISIN
CA0717341071
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Thomas J. Appio
Employee Count
-
Website
https://www.bauschhealth.com
Ipo Date
1996-04-03
Details
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.